We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
GLOBE SCIENTIFIC, LLC

Download Mobile App





Gentian Diagnostics Exhibits Assays for Wide Range of Clinical Chemistry Platforms at EUROMEDLAB

By LabMedica International staff writers
Posted on 11 Apr 2022

Gentian Diagnostics (Moss, Norway) exhibited its range of assays for highly relevant biomarkers for a wide range of clinical chemistry platforms at the 24th IFCC-EFLM European Congress of Clinical Chemistry and Laboratory Medicines (EUROMEDLAB) in Munich, Germany. More...

Gentian demonstrated its Calprotectin Immunoassay (GCAL) assay, which is the first turbidimetric assay for the quantitative measurement of calprotectin in plasma and serum intended as an aid in the detection and assessment of inflammation. Calprotectin in plasma and serum is a sensitive and early biomarker in detection of inflammation and inflammatory response in infections. Calprotectin has been reported as diagnostic marker in the discrimination between bacterial and viral infection, in assessment of severe infections and sepsis and in the prediction for development of severe infections. Interestingly, calprotectin has also been reported a risk marker in severe COVID-19, which in contrast to other viral infection induces a hyperinflammation response and pathways mimic bacterial sepsis. Gentian’s GCAL is an open channel assay, meaning it can be added to all clinical chemistry analyzers.

Gentian also promoted its turbidimetric Cystatin C Immunoassay which is a Particle-Enhanced Turbidimetric Immunoassay (PETIA) for in vitro testing of cystatin C in human plasma and serum samples. Cystatin C is a superior glomerular filtration rate (GFR) marker for the diagnosis and therapeutic control of renal function1 for patients of all ages. The Cystatin C Immunoassay has documented high inter-instrument accuracy on a wide range of clinical chemistry analyzers. Gentian also promoted its new turbidimetric SARS-CoV-2 Total Antibody Immunoassay which is a quantitative antibody test that captures the full immune response detecting antibodies targeting the S1-subunit with high sensitivity and specificity. It will be calibrated against the international WHO international standard. Since the Gentian assay is platform agnostic, it can be seamlessly integrated in daily laboratory routine without additional infrastructure or workflow cost. The test follows a standard testing protocol utilizing existing logistic structure, from the routine blood test at the GP office to the clinical chemistry platforms with an assay time of only 10 minutes.

Related Links:
Gentian Diagnostics 


Gold Member
Serological Pipet Controller
PIPETBOY GENIUS
3-Part Differential Hematology Analyzer
Swelab Alfa Plus Sampler
New
C-Reactive Protein Rapid Test
Afinion CRP
New
Glucose Tolerance Test
NERL Trutol
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image: Non-coding RNAs CBR3-AS1 and PCA3 can be utilized as therapeutic targets and prognostic biomarkers in gastric cancer (Photo courtesy of Adobe Stock)

Promising Molecular Markers Support Earlier Diagnosis of Gastric Cancer

Late detection continues to make gastric cancer one of the leading causes of cancer-related deaths globally. With improved early detection tools urgently needed, researchers have now identified two long... Read more

Hematology

view channel
Image: CitoCBC is the world first cartridge-based CBC to be granted CLIA Waived status by FDA (Photo courtesy of CytoChip)

Disposable Cartridge-Based Test Delivers Rapid and Accurate CBC Results

Complete Blood Count (CBC) is one of the most commonly ordered lab tests, crucial for diagnosing diseases, monitoring therapies, and conducting routine health screenings. However, more than 90% of physician... Read more

Immunology

view channel
Image: The tip optofluidic immunoassay platform enables rapid, multiplexed antibody profiling using only 1 μL of fingertip blood (Photo courtesy of hLife, DOI:10.1016/j.hlife.2025.04.005)

POC Diagnostic Platform Performs Immune Analysis Using One Drop of Fingertip Blood

As new COVID-19 variants continue to emerge and individuals accumulate complex histories of vaccination and infection, there is an urgent need for diagnostic tools that can quickly and accurately assess... Read more

Pathology

view channel
Image: The new technology combines a rapid hemoglobin test with a smartphone app (Photo courtesy of 123RF)

Smartphone-Based Rapid Hemoglobin Test Accurately Detects Colorectal Cancer

Despite the availability of colorectal cancer screening programs, participation remains low, especially for fecal immunochemical tests (FIT), a non-invasive method to detect hidden blood in the stool.... Read more

Technology

view channel
Image: The machine learning-based method delivers near-perfect survival estimates for PAC patients (Photo courtesy of Shutterstock)

AI Method Predicts Overall Survival Rate of Prostate Cancer Patients

Prostate adenocarcinoma (PAC) accounts for 99% of prostate cancer diagnoses and is the second most common cancer in men globally after skin cancer. With more than 3.3 million men in the United States diagnosed... Read more
Copyright © 2000-2025 Globetech Media. All rights reserved.